Epigral Ltd
Epigral Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.
From Epigral Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years.
- Growth driven by ramping up existing capacities (chlorotoluenes, caustic soda, CPVC) and commissioning new capacities such as Epoxy Resin, Epichlorohydrin (ECH), and multipurpose plants.
- The company aims to expand from approximately INR2,500 crores current revenue to around INR3,000-3,500 crores in the near term, and with all plants at optimal utilization, the top line could reach INR4,000+ crores over time.
- Domestic demand, especially in infrastructure, renewable energy, automotive, and pharmaceutical/agrochemical intermediates, is expected to sustain double-digit volume growth.
2 more points from Epigral Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Epigral Limited has approved a strategic capex plan for two new projects:
- Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.
- A Multipurpose Plant (MPP) to manufacture downstream products of epichlorohydrin and chlorotoluenes value chain.
- Total capex in chlorotoluenes around INR 250 crores has been done.
- Combined peak revenue expected post these projects is INR 1,300 to 1,500 crores.
- Overall capex including the MPP is expected to result in consolidated top line in the range of INR 700 to 800 crores initially.
- Capex split: 40% internal accruals, 60% debt.
- Estimated EBITDA margin for chlorotoluenes/MPP around 22%-23%.
2 more points from Epigral Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Epigral Ltd's call on order book
Create a free account to keep reading this call
Epigral Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹736 Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
- POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
- Devson Catalyst Ltd (Q1 FY27)
FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee
- Ambani Orgochem (Q1 FY27)
Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Epigral Ltd Q1 FY27 results?
Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 15.8 with a market cap of ₹4,296 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Epigral Limited has approved a strategic capex plan for two new projects: - Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.